EchoIQ Expands Mayo Clinic Deal to 80+ US Hospitals Ahead of FDA Decision
Key Takeaways
EchoIQ Limited has expanded its EchoIQ Mayo Clinic Partnership Agreement to a potential 6-year term covering Mayo hospitals and more than 80 external partner institutions, positioning the company for rapid commercial deployment upon FDA clearance of its EchoSolv HF heart failure diagnostic tool.
- Echo IQ has expanded and improved its distribution agreement with Mayo Clinic, extending the potential term to 6 years with an automatic 3-year renewal clause, replacing the original April 2025 arrangement.
- The agreement grants access to Mayo hospitals, its broader health system network, and more than 80 external partner hospitals via the Mayo Clinic Platform — without requiring Echo IQ to build hospital-by-hospital sales infrastructure.
- EchoSolv HF demonstrated 99.5% sensitivity and 91.1% specificity in a November 2025 validation study, underpinning the FDA 510(k) application lodged in December 2025 which remains under review.
- The addressable US market includes approximately 16 million annual echocardiograms, with around 2 million Americans currently undiagnosed for heart failure, representing a substantial commercial opportunity contingent on regulatory clearance.
Echo IQ expands Mayo Clinic distribution agreement ahead of FDA decision
EchoIQ Limited (ASX: EIQ) has expanded and improved its commercial agreement with the Mayo Foundation for Medical Education and Research for the distribution of its heart failure clinical decision support solution, EchoSolv HF. The EchoIQ Mayo Clinic Partnership Agreement positions the company to potentially generate revenue upon receiving clearance from the US Food and Drug Administration (FDA), with distribution extending to Mayo hospitals, the health system network, and more than 80 external partner hospitals via the Mayo Clinic Platform.
The revised agreement runs for a potential 6-year term, comprising an initial 3-year period followed by an automatic 3-year renewal. This development arrives whilst the company’s FDA 510(k) application, lodged in December 2025, remains under review. By establishing distribution infrastructure before regulatory clearance, Echo IQ has removed a key post-approval execution risk that many medical technology companies face during commercial deployment.
When big ASX news breaks, our subscribers know first
What is the Mayo Clinic Platform and why does it matter?
The Mayo Clinic Platform operates a Solutions Studio Program that functions as a distribution channel for healthcare technology. Rather than requiring Echo IQ to build direct sales infrastructure hospital-by-hospital, this platform-enabled model provides immediate access to Mayo’s network and external partner institutions once FDA clearance is obtained.
Mayo Clinic ranks among the top hospital systems in the United States, recognised for excellence across multiple medical specialties including cardiology and cardiovascular surgery. The organisation operates major campuses in Rochester, Minnesota; Phoenix/Scottsdale, Arizona; and Jacksonville, Florida, alongside a broader health system and the Mayo Clinic Care Network.
For investors, this distribution model reduces go-to-market costs and accelerates the adoption timeline. Instead of deploying field sales teams to establish relationships with individual hospitals, Echo IQ gains potential access to an established network through a single partnership. This approach is particularly relevant for emerging medical technology companies seeking to minimise capital requirements during commercial rollout.
Improved commercial terms strengthen Echo IQ’s position
The expanded agreement replaces the original terms established in April 2025. According to the company, the revised arrangement reflects “a more equitable financial arrangement between the parties” and now includes the automatic 3-year renewal clause, extending the potential commercial partnership to 6 years.
This renegotiation follows the successful validation study completed in November 2025, where EchoSolv HF demonstrated 99.5% sensitivity in identifying patients with heart failure and 91.1% specificity in correctly identifying patients without the condition. The company subsequently lodged its FDA application via the 510(k) premarket notification pathway in December 2025.
Dustin Haines, Chief Executive Officer
“The expansion of our agreement with Mayo Clinic is one of the more strategically important milestones in the Company’s history. A more equitable arrangement with one of the most respected hospital systems in the US, as we move closer to FDA clearance and commercial deployment, leaves us well positioned for the months ahead.”
The improved terms suggest growing commercial value of EchoSolv HF as the FDA decision approaches. For a pre-revenue medical technology company, securing favourable distribution agreements before regulatory clearance can indicate institutional confidence in the technology’s clinical utility and market potential.
Heart failure market presents substantial US opportunity
Heart failure represents a significant burden on the US healthcare system, with a clear diagnostic gap that EchoSolv HF is designed to address. The product integrates within existing echocardiogram workflows, targeting a large addressable market where approximately 50% of heart failure cases are not accurately diagnosed.
Key market statistics:
| Metric | Figure |
|---|---|
| Americans with heart failure | ~6.7 million |
| Undiagnosed patients | ~2 million |
| Annual US echocardiograms | ~16 million |
| Studies with HF-relevant findings | ~8 million |
| Lifetime risk for Americans | 1 in 4 |
Approximately 16 million echocardiograms are performed annually in the United States, with around 8 million studies containing heart failure-relevant findings. This represents roughly 50% of all echocardiographic examinations. The clinical need is further emphasised by the fact that 1 in 4 Americans is expected to develop heart failure in their lifetime.
The large addressable market with clear diagnostic gaps validates the commercial opportunity if FDA clearance is obtained. However, market size alone does not guarantee commercial success. Execution will depend on reimbursement coverage, adoption rates by healthcare professionals, and the company’s ability to convert partnerships into revenue-generating installations.
The next major ASX story will hit our subscribers first
Path to commercialisation and next steps
Echo IQ’s FDA 510(k) application is currently under review, with the company progressing through the regulatory process. The 510(k) pathway is used for medical devices that are substantially equivalent to legally marketed devices, typically offering a faster clearance route than the more rigorous premarket approval (PMA) pathway.
Whilst the FDA review continues, the company’s focus centres on preparing for rapid commercial rollout and expanding its network of US healthcare partners. All commercial arrangements, distribution rights, and deployment activities remain contingent upon receiving FDA clearance.
Key milestones to monitor:
- FDA 510(k) clearance decision for EchoSolv HF
- Initial deployment via Mayo Clinic Platform upon clearance
- Expansion of US healthcare partner network
- Revenue generation from commercial installations
- Reimbursement coverage developments across payer networks
The expanded Mayo Clinic distribution agreement de-risks the post-clearance commercialisation phase by establishing infrastructure before regulatory approval. For investors, the FDA decision becomes the key near-term catalyst. However, it is important to note that there can be no assurance regarding the timing or outcome of the FDA review process, and the validation study results have not been reviewed or cleared by the FDA.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to receive real-time alerts the moment market-moving announcements break across the sector.